|
Sensitivity and specificity of ANA and its clinically important subtypes [18,19] |
|||
| Autoantibodies |
Associated CTD |
Sensitivity |
Specificity |
|
|
|||
| ANA |
SLE |
93 |
57 |
| Sjogren's syndrome |
48 |
52 |
|
| SS |
85 |
54 |
|
| PM/dermatomyositis |
61 |
63 |
|
| Raynaud phenomena |
64 |
41 |
|
|
|
|||
| Specific ANA |
|||
| Anti-dsDNA |
SLE |
57 |
97 |
| Anti-Sm |
SLE |
25–30 |
High* |
| Anti-SSA/Ro |
Sjogren's syndrome, subacute cutaneous SLE, Neonatal lupus syndrome |
8–70 |
87 |
| Anti-SSB/La |
Sjogren's syndrome, subacute cutaneous SLE, Neonatal lupus syndrome |
16–40 |
94 |
| Anti-U3-RNP |
SS |
12 |
96 |
| Anticentromere |
Limited cutaneous SS |
65 |
99.9 |
| Scl-70 |
SS |
20 |
100 |
| Jo-1 |
PM |
30 |
95 |
|
* Precise data not available. | |||
Kumar et al. Diagnostic Pathology 2009 4:1 doi:10.1186/1746-1596-4-1 |
|||